The Lung Cancer Channel is supported with funding from Johnson & Johnson (Gold) and Takeda (Gold).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ISLB 2021 | Potential of liquid biopsy in NSCLC
David Gandara, MD, UC Davis Comprehensive Cancer Center, Sacramento, CA, discusses the role of liquid biopsy in non-small cell lung cancer (NSCLC). Liquid biopsy has potential uses across the whole spectrum of cancer care, from early diagnosis and screening, to post-treatment monitoring. Liquid biopsy is particularly useful for the field of NSCLC, as there are a wide variety of drug targets which the extensive molecular profiling capabilities of liquid biopsy can help to identify. This will help to develop personalised treatment regimens for patients, which are likely to lead to better survival outcomes. This interview took place at the International Society of Liquid Biopsy 2021 Virtual Meeting.
